MEI Pharma Inc (MEIP) - Total Liabilities
Based on the latest financial reports, MEI Pharma Inc (MEIP) has total liabilities worth $1.35 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MEI Pharma Inc net asset momentum to track the company's year-over-year net asset growth rate.
MEI Pharma Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how MEI Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See MEI Pharma Inc (MEIP) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
MEI Pharma Inc Competitors by Total Liabilities
The table below lists competitors of MEI Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kura Sushi Asia Co Ltd
TWO:2754
|
Taiwan | NT$3.29 Billion |
|
Uni Charm Indonesia PT
JK:UCID
|
Indonesia | Rp2.75 Trillion |
|
CLERHP Estructuras S.A
MC:CLR
|
Spain | €74.25 Million |
|
Haitai Confectionery and Foods Co Ltd
KO:101530
|
Korea | ₩417.45 Billion |
|
Taegu Broadcasting Corporation
KQ:033830
|
Korea | ₩6.35 Billion |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
Israel | ILA807.85 Million |
|
Westag & Getalit ST O.N.
F:WUG
|
Germany | €47.09 Million |
|
Spanish Mountain Gold Ltd
V:SPA
|
Canada | CA$1.60 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down MEI Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MEIP company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MEI Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MEI Pharma Inc (2002–2025)
The table below shows the annual total liabilities of MEI Pharma Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.35 Million | -83.79% |
| 2024-06-30 | $8.36 Million | -91.31% |
| 2023-06-30 | $96.19 Million | -23.31% |
| 2022-06-30 | $125.43 Million | -5.51% |
| 2021-06-30 | $132.74 Million | +0.93% |
| 2020-06-30 | $131.51 Million | +278.63% |
| 2019-06-30 | $34.73 Million | -35.91% |
| 2018-06-30 | $54.20 Million | +1013.81% |
| 2017-06-30 | $4.87 Million | -11.72% |
| 2016-06-30 | $5.51 Million | +11.15% |
| 2015-06-30 | $4.96 Million | +7.43% |
| 2014-06-30 | $4.62 Million | +175.58% |
| 2013-06-30 | $1.68 Million | -5.58% |
| 2012-06-30 | $1.77 Million | -25.27% |
| 2011-06-30 | $2.37 Million | +35.27% |
| 2010-06-30 | $1.75 Million | -57.64% |
| 2009-06-30 | $4.14 Million | +20.33% |
| 2008-06-30 | $3.44 Million | +37.01% |
| 2007-06-30 | $2.51 Million | +99.44% |
| 2006-06-30 | $1.26 Million | -55.68% |
| 2005-06-30 | $2.84 Million | +49.08% |
| 2004-06-30 | $1.91 Million | +40.95% |
| 2003-06-30 | $1.35 Million | +351.00% |
| 2002-06-30 | $300.00K | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more